Website: rexahn.com
SEC Filings: sec.gov
Press Releases: rexahn.com
Portfolio: rexahn.com
Lead drug candidates in Phase II trials:
Serdaxin® a best-in-class therapy for treating depression, and potentially Parkinson’s Disease and Alzheimer’s Disease. (April, 2010 Phase II protocol submitted to FDA for PD. April, 2010 - positive Phase IIa results for treatment of depression, Phase IIb to being second half of 2010.)
Zoraxel™ a first-in-class CNS-based therapy for treating sexual dysfunction. (March 2010 Phase IIb protocol submitted to FDA)
Archexin® a first-in-class AKT-inhibitor therapy for treating various cancers, such as pancreatic cancer, renal cell carcinoma (RCC), glioblastoma, and cancers of the ovary and stomach. (Phase II initiated in March 2009, results on humans expected in 2010.) |
